• Pennsylvania jury orders Johnson & Johnson to pay damages in a talc baby powder case related to alleged cancer risks.
• Verdict arrives as more talc trials are scheduled across the US, with thousands of related lawsuits still pending.
• US FDA approves a new monthly dosing schedule for RYBREVANT FASPRO as a first line lung cancer treatment.

For investors watching Johnson & Johnson (NYSE:JNJ), this mix of legal and drug development news comes with the stock recently trading at about $243.33. The share price sits alongside multi period gains, including 2.1% over the past week, 11.3% over the past month, 17.4% year to date, and 60.5% over the past year. Longer term returns of 67.5% over three years and 73.7% over five years show how the market has priced the business through different cycles.

Looking ahead, the talc verdict and upcoming trials keep legal risk in focus, while the updated RYBREVANT FASPRO dosing schedule adds another data point in the company’s oncology pipeline. As you think about Johnson & Johnson, these developments may be useful markers when comparing its risk profile and product mix with other large healthcare names.

Stay updated on the most important news stories for Johnson & Johnson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Johnson & Johnson.

Quick Assessment

• ❌ Price vs Analyst Target: At US$243.33, the share price is about 5% above the US$231.25 analyst consensus target.
• ✅ Simply Wall St Valuation: Shares are described as trading 36.4% below an estimated fair value.
• ✅ Recent Momentum: The 30 day return of roughly 11.3% points to solid short term strength.

There is only one way to know the right time to buy, sell or hold Johnson & Johnson. Head to Simply Wall St's company report for the latest analysis of Johnson & Johnson's Fair Value.

Key Considerations

• 📊 The talc verdict keeps legal overhang in play, while the RYBREVANT FASPRO update adds another approved option in oncology.
• 📊 Watch how legal provisions, oncology revenue disclosures and any changes to analyst targets line up with the current US$243.33 price.
• ⚠️ The cluster of ongoing talc trials is a key risk for future cash outflows and could affect sentiment even alongside positive drug news.

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Johnson & Johnson analysis. Alternatively, you can visit the community page for Johnson & Johnson to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.